Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
16. Juni 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
Pernix Therapeutics Reports First Quarter 2016 Financial Results and Business Update
05. Mai 2016 08:00 ET
|
Pernix Therapeutics Holdings, Inc.
Pernix Prescriptions DirectTM Achieves Increased Penetration MORRISTOWN, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a...
Pernix Therapeutics Holdings, Inc. Announces Positive Interim Results From a Phase IV Study to Assess and Compare the Effects of Silenor 6 mg and zolpidem 10 mg on Balance, Cognitive Performance, and Arousability
12. November 2015 11:15 ET
|
Pernix Therapeutics Holdings, Inc.
MORRISTOWN, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced positive interim results from a Phase IV...